Allogene Therapeutics, Inc.

NasdaqGS:ALLO 주식 보고서

시가총액: US$524.2m

Allogene Therapeutics 관리

관리 기준 확인 2/4

Allogene Therapeutics CEO는 David Chang, Jun2018 에 임명되었습니다 의 임기는 6.42 년입니다. 총 연간 보상은 $ 14.06M, 5.1% 로 구성됩니다. 5.1% 급여 및 94.9% 보너스(회사 주식 및 옵션 포함). 는 $ 19.31M 가치에 해당하는 회사 주식의 3.68% 직접 소유합니다. 19.31M. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 6.6 년입니다.

주요 정보

David Chang

최고 경영자

US$14.1m

총 보상

CEO 급여 비율5.1%
CEO 임기6.4yrs
CEO 소유권3.7%
경영진 평균 재임 기간1.7yrs
이사회 평균 재임 기간6.6yrs

최근 관리 업데이트

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Recent updates

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 27

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22
We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27
Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

Oct 06

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Sep 22
An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Sep 13

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Aug 09

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

CEO 보상 분석

David Chang 의 보수는 Allogene Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$283m

Jun 30 2024n/an/a

-US$279m

Mar 31 2024n/an/a

-US$292m

Dec 31 2023US$14mUS$724k

-US$327m

Sep 30 2023n/an/a

-US$344m

Jun 30 2023n/an/a

-US$365m

Mar 31 2023n/an/a

-US$361m

Dec 31 2022US$15mUS$724k

-US$340m

Sep 30 2022n/an/a

-US$313m

Jun 30 2022n/an/a

-US$308m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$10mUS$695k

-US$182m

Sep 30 2021n/an/a

-US$251m

Jun 30 2021n/an/a

-US$239m

Mar 31 2021n/an/a

-US$229m

Dec 31 2020US$8mUS$675k

-US$316m

Sep 30 2020n/an/a

-US$243m

Jun 30 2020n/an/a

-US$227m

Mar 31 2020n/an/a

-US$207m

Dec 31 2019US$11mUS$600k

-US$185m

Sep 30 2019n/an/a

-US$154m

Jun 30 2019n/an/a

-US$147m

Mar 31 2019n/an/a

-US$240m

Dec 31 2018US$13mUS$362k

-US$212m

보상 대 시장: David 의 총 보상 ($USD 14.06M )은 US 시장( $USD 2.12M ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Chang (64 yo)

6.4yrs

테뉴어

US$14,061,848

보상

Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...

리더십 팀

이름위치테뉴어보상소유권
Arie Belldegrun
Co-Founder & Executive Chairman7yrsUS$9.36m2.92%
$ 15.3m
David Chang
Co-Founder6.4yrsUS$14.06m3.68%
$ 19.3m
Joshua Kazam
Co-Founder & Directorno dataUS$684.49k0.14%
$ 757.7k
Timothy Moore
Executive VP & Chief Technical Officer1.6yrsUS$5.80m0.13%
$ 663.7k
Zachary Roberts
Executive VP of Research & Development and Chief Medical Officer1.8yrsUS$8.13m0.018%
$ 95.7k
Geoffrey Parker
Executive VP & CFO1.1yrs데이터 없음0.54%
$ 2.8m
Annie Yoshiyama
Senior VPless than a year데이터 없음데이터 없음
Earl Douglas
Senior VP1.3yrs데이터 없음0.21%
$ 1.1m
Susan Lundeen
Chief People Officer2.5yrs데이터 없음데이터 없음
Christine Cassiano
Executive VP1.8yrs데이터 없음데이터 없음
Yinlin Chen
Senior Vice President of Financeno data데이터 없음0.042%
$ 222.2k
David Tanen
Secretaryno data데이터 없음데이터 없음

1.7yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: ALLO 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
Arie Belldegrun
Co-Founder & Executive Chairman7yrsUS$9.36m2.92%
$ 15.3m
David Chang
Co-Founder6.4yrsUS$14.06m3.68%
$ 19.3m
Joshua Kazam
Co-Founder & Director7yrsUS$684.49k0.14%
$ 757.7k
David Bonderman
Lead Independent Director6.6yrs데이터 없음데이터 없음
Franz Humer
Independent Director6.6yrsUS$585.00k0.15%
$ 791.8k
Owen Witte
Independent Director6.6yrsUS$510.00k0.12%
$ 638.9k
Todd Sisitsky
Independent Director6.6yrs데이터 없음데이터 없음
Deborah Messemer
Independent Director6.2yrsUS$495.00k0.080%
$ 416.9k
Matthew Porteus
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Donald Kohn
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Antonius Schumacher
Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
John DeYoung
Independent Director6.6yrs데이터 없음데이터 없음

6.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: ALLO 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.